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Aims More than two billion people worldwide are deficient in key micronutrients. Single micronutrients have been used at
high doses to prevent and treat dietary insufficiencies. Yet the impact of combinations of micronutrients in small
doses aiming to improve lipid disorders and the corresponding metabolic pathways remains incompletely under-
stood. Thus, we investigated whether a combination of micronutrients would reduce fat accumulation and athero-
sclerosis in mice.
Methods
and results
Lipoprotein receptor-null mice fed with an original combination of micronutrients incorporated into the daily chow
showed reduced weight gain, body fat, plasma triglycerides, and increased oxygen consumption. These effects were
achieved through enhanced lipid utilization and reduced lipid accumulation in metabolic organs and were mediated, in
part, by the nuclear receptor PPARa. Moreover, the micronutrients partially prevented atherogenesis when adminis-
tered early in life to apolipoprotein E-null mice. When the micronutrient treatment was started before conception,
the anti-atherosclerotic effect was stronger in the progeny. This finding correlated with decreased post-prandial tri-
glyceridaemia and vascular inflammation, two major atherogenic factors.
Conclusion Our data indicate beneficial effects of a combination of micronutritients on body weight gain, hypertriglyceridaemia,
liver steatosis, and atherosclerosis in mice, and thus our findings suggest a novel cost-effective combinatorial micro-
nutrient-based strategy worthy of being tested in humans.
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1. Introduction
Disorders of lipid metabolism generally result in excessive fat storage,
not only in adipose tissue but also in other organs such as liver and
arteries. Fat accumulation in hepatocytes results in fatty liver; in
arteries, it may result in atherosclerotic plaques. Fatty liver is usually
asymptomatic, but 35% of obese individuals with fatty liver will
progress to cirrhosis compared with 10% in the general population.1
Ultimately, cirrhosis may lead to liver cancer.2 Obesity is also known
to be associated with a systemic inflammatory state that induces
endothelial dysfunction, thereby favouring atherogenesis.3 In fact,
endothelial cell activation enhances recruitment of macrophages
into the subendothelial space where they promote atherosclerotic
plaque formation.4 Rupture of an atherosclerotic plaque may cause
myocardial infarction, the leading cause of mortality in Western
countries.
The high morbidity associated with obesity warrants preventive
measures. Strategies for weight gain prevention address socio-
environmental factors by promoting healthy nutrition and regular
exercise. Unfortunately, there is little evidence for lasting effects of
these interventions.5 Plasma lipid-lowering drugs are most commonly
used to reduce obesity-related complications,6 but so far, no effective
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approach is available for prevention of both obesity and its cardiovas-
cular complications.
We hypothesized that combinations of micronutrients may meet
this challenge. The most recent definition of a micronutrient from
Mosby’s Medical Dictionary (2009) describes them as ‘any dietary
element essential only in minute amounts for the normal physiologic
processes of the body, including vitamins and minerals or chemical
elements, such as zinc or iodine’. Most studies have evaluated the ben-
eficial effects of one micronutrient on a single parameter of lipid
metabolism. We still do not know all dietary elements that are essen-
tial for its fine-tuning, but different micronutrients must cooperate to
allow optimal cell activity.7
In the present study, we test an original combination of specific
micronutrients, which comprises several phyto-ingredients and oils
with beneficial effects on lipid metabolism (Supplementary material
online, Table S1). In fact, bioactive phytochemicals have been pro-
posed for the prevention and treatment of diabetic complications
and natural product libraries are a rich source of PPAR modulators
in the treatment of cardiometabolic syndrome.8,9 We anticipated
that when assembled in well-defined proportions, such ingredients
combined to classic micronutrients would cooperate to produce
effects at low concentrations. We show herein that the combination
called lipistase10 meets this expectation and reduces body weight gain,
plasma lipids, hepatic steatosis, and atherosclerosis in mice deficient in
low-density lipoprotein receptor (LDLrKO) or in apolipoprotein E
(APOEKO), two common models for investigating adiposity or ather-
osclerosis, respectively.
2. Methods
2.1 Ethics statement
All experiments involving animals described herein were approved by the
Veterinary Office of the Canton Vaud (Switzerland) (authorizations
1868.1, 1868.2, and 1868.3) in accordance with the Federal Swiss Veter-
inary Office Guidelines and conform to the European Commission Direc-
tive 86/609/EEC. Blood collection and cervical dislocation were carried
out after anaesthesia with 1.45% isoflurane. Depth of anaesthesia was
monitored by toe pinch reflex test.
2.2 Animals
The mouse strains used are established models for lipid disorder studies
and are either deficient in the receptor of low-density lipoprotein
(LDLrKO mice, four 9-week-old males per group) or apolipoprotein E
(APOEKO mice, ten 3-week-old males per group; ten 10-week-old
males per group, and fifteen males per group for the antenatal study).
LDLrKO-PPARaKO mice (five 9-week-old males per group) were used
to assess the importance of PPARa in the effects of lipistase. All mice
had free access to food and water.
2.3 Diet and micronutrition
Mice were fed a standard chow (3436, Provimi Kliba, Switzerland) for
3 months (antenatal treated mice) or 10 months (long-term treated
mice). The micronutrient combination lipistase10 was added to this diet
before pelleting, using soy oil with or without lipistase given at a concen-
tration of 17 mg/L for a final concentration in food of 350 ng/kg. Litter-
mate control mice were fed with the same standard chow without
lipistase. Trace elements, vitamins, and minerals are already present in
chow diet and are only marginally increased in the lipistase diet
(in total, 174.9 ng more per kg of diet). The ingredients that are
exclusively contained in the lipistase diet are the oils and the plant
extracts, as detailed in Supplementary material online, Table S1.
2.4 Body weight, fat mass, PPARa
transactivation assay, and mRNA levels
Mice were weighed before treatment and monthly during the study. In
parallel, food intake was monitored. The body fat mass was measured
with an EchoMRI apparatus (Colombus Instruments, Ohio, USA).
PPARa transactivation assay was performed using the GAL4/UAS
system. NIH3T3 cells were transfected with either GAL4 alone or
GAL4 fused to the PPARa ligand-binding domain (LBD), in addition to
a luciferase reporter plasmid. Renilla reporter plasmid was used as a
transfection control. The four plasmids used for this transfection,
GAL4, GAL4-LBD, 5xUAS-TK-LUC, and RENILLA, were from our
in-house stocks. SuperFect Transfection Reagent (QIAGEN, Switzerland)
and the Luciferase Assay System (Promega, Switzerland) were used
according to the manufacturers’ recommendations. After transfection,
cells were incubated with different compounds in a starved medium
for 24 h before harvesting. The extraction of RNA and its analysis by
RT–qPCR were according to standard procedures. The values were nor-
malized to those obtained for a housekeeping mRNA. Sequences of the
oligonucleotides used are given in the Supplementary material online,
Table S2.
2.5 Lipid utilization
Blood was collected via retro-orbital puncture and plasma was recov-
ered by centrifugation. Triglyceride plasma levels were measured using
a Roche Diagnostics/Hitachi 902 analyzer (Mannheim, Germany). Paraf-
fin embedded LDLrKO mice gastrocnemius muscle samples were sec-
tioned (4 mm) and incubated 2 h at 378C with 1/200 diluted rabbit
polyclonal anti-CD36 antibody (Novus Biologicals, Inc. Littleton, CO,
USA). Immunostaining was via a fluorescent secondary antibody, goat
anti-rabbit Alexa 568 (Invitrogen, Basel, Switzerland). For CD36 quanti-
fication by immunoblotting, 4 mg and 6 mg of cytosolic and membrane
extracts, respectively, were loaded and probed with 1/1000 rabbit poly-
clonal anti-CD36 antibody (Novus Biologicals, Inc. Littleton, CO, USA).
An indirect calorimetric analysis, measuring respiratory gases, was
performed at the end of the study. Mice were acclimatized in the calori-
meter cages of Oxymax/Comprehensive Lab Animal Monitoring System
(CLAMS, Columbus Instruments, Columbus, OH, USA) for 24 h and
then oxygen consumption was measured for an additional 24 h.
2.6 Adipogenesis
After 10 months, the lipistase-treated LDLrKO mice and the untreated
controls were anaesthetized with 1.45% isoflurane and sacrificed.
Adipose tissue and liver samples were paraffin embedded. Sections of
4 mm thickness were stained with haematoxylin–eosin and histology
was studied under an optic microscope. Rat anti-F4/80 antibody
(Abcam, Cambridge, UK) was used to stain adipose tissue macrophages
and the immunostaining was revealed by an anti-rat HRP (Invitrogen,
Basel, Switzerland).
For the adipogenesis assay, we used the pre-adipocytes 3T3L1 cells
(in-house stock) at 2 days post-confluence (day 0). We first incubated the
cells for 2 days with 16 mL/mL of the cocktail IBMX (10 mM)/dexamethasone
(50 mM)/insulin (10 mg/mL) (Sigma, Buchs, Switzerland) in order to induce
their differentiation into adipocytes able to accumulate lipids. During the
induction phase, the cells were also treated with either rosiglitazone
(1 mM) alone (Alexis Biochemicals, Lausen, Switzerland) or with rosiglita-
zone (1 mM) and lipistase (160 pg/mL). At day 3, the cells were incubated
with these treatments without the cocktail for 5 days. The medium was
changed every 2 days during the whole assay. At day 8, cells were fixed
with PFA 4% for 10 min and stained with Oil-red O for 10 min. After
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washing, the optic density of each plate was measured with a spectropho-
tometer at a wavelength of 520 nm.
2.7 Hepatic neutral lipids content
Hepatic cholesterol, cholesterol esters, and triglycerides were determined
by gas chromatography analysis as described elsewhere11 from snap
frozen liver biopsies.
2.8 Atherosclerosis
APOEKO mice treated from the age of 3 or 10 weeks were sacrificed
after 3 or 10 months of treatment, respectively, and the aortic roots
were dissected. In the antenatal study, the pups of lipistase-treated
APOEKO mice were again treated for 3 months after weaning and
were then sacrificed (the parents were treated 1 month before mating,
and the mothers during pregnancy and lactation). Atherosclerotic
plaques were quantified in cryo-cross-sections (8 mm thickness) of
aortic roots stained with Oil-red O using digital morphometry (Igor6,
Wavemetrics Inc., Lake Oswego, USA). Rat monoclonal anti-vascular
cell adhesion molecule 1 (VCAM1) and anti-CD68 antibodies, and
rabbit polyclonal anti-a smooth muscle actin (aSMA) antibody
(Abcam, Cambridge, UK) were used on frozen sections of antenatal-
treated aortic roots. The immunostaining was revealed by a fluorescent
secondary antibody, goat anti-rat/rabbit Alexa 568 (Invitrogen, Basel,
Switzerland). For the postprandial plasma triglyceride test, APOEKO
mice after 3 months treatment with lipistase or vehicle from the ante-
natal study were fasted for 12 h. After fasting, they received 300 mL of
soy oil containing or not lipistase (17 mL/L) by oral gavages and blood
samples were collected before gavages (time 0) and every hour during
5 h.
2.9 Statistics
Analysis of variance for repeated measurements, paired or unpaired t-test,
was used where appropriate. Normal distribution was tested using the
Shapiro Wilk’s test (SPSS13, SPSS Inc. and Prizm, GraphPad Inc.). Values
are expressed as mean+ SEM.
3. Results
3.1 Body weight, fat mass, and circulating
triglycerides
Lipistase comprises 26 ingredients, including trace metals, minerals,
vitamins, phyto-ingredients, and oils designed to impact lipid metab-
olism.10 To assess the effects of long-term lipistase treatment on
body weight, three mouse strains (LDLrKO, LDLrKO-PPARaKO,
and APOEKO) received the combinatorial micronutrient preparation
at low doses in the daily chow for up to 10 months. Control litter-
mates received the same diet without micronutrients. Despite a
similar food intake (Supplementary material online, Figure S1), the
treated LDLrKO and APOEKO mice gained less weight, developed
less fat mass, and showed reduced plasma triglyceride levels when
compared with untreated mice (Figure 1A and C ). Interestingly,
these differences were reduced in micronutrient-treated
LDLrKO-PPARaKO mice compared with their control littermates,
suggesting a role of the nuclear receptor PPARa in mediating the
effects of lipistase (Figure 1B). This was further supported by the
almost two-fold increase of fat accumulation in lipistase-treated
LDLrKO-PPARaKO compared with the lipistase-treated LDLrKO
mice. The untreated LDLrKO-PPARaKO mice also accumulated
more fat than the LDLrKO mice, but to a lesser extent. In addition,
the LDLrKO-PPARaKO animals accumulated three–four-fold more
neutral lipids in their liver (see below), which together with their
increased adiposity may explain their unchanged triglyceride levels
during the course of the experiment (Figure 1B). These observations
prompted us to investigate whether lipistase activates PPARa, a major
regulator of lipid homeostasis including blood triglyceride levels.12,13
Using NIH3T3 cells and the GAL4/UAS system as transactivation
assay for the PPARa LBD (Figure 1D), we observed a dose-dependent
PPARa activation by lipistase, reaching levels obtained with the syn-
thetic PPARa ligand, WY-14 643, and exceeding the level of activation
by several lipistase phyto-ingredients tested individually. Moreover,
this assay showed that evening primrose oil is a powerful PPARa
activator. Taken together, these results indicate that lipistase
reduces weight gain in different mouse models by decreasing fat
mass expansion. PPARa may participate in these beneficial effects.
3.2 Lipid utilization in muscle
Skeletal muscle is the primary site of lipid utilization.14 Thus, we inves-
tigated the effects of lipistase on the expression of CD36, a key factor
involved in lipid uptake and utilization.15 LDLrKO mice treated with
lipistase for 10 months expressed higher levels of CD36 mRNA and
protein in muscle (Figure 2A and C ). Consistent with enhanced lipid
oxidation, the mRNA levels of the peroxisomal bifunctional enzyme
(BFE) and mitochondrial uncoupling protein 3 (UCP3) as well as
oxygen consumption were significantly higher in lipistase-treated
LDLrKO mice compared with controls (Figure 2B and C). These
results suggest a lipistase-dependent stimulation of muscle oxidative
activity.
3.3 Lipid storage and macrophage
recruitment in white adipose tissue
By increasing lipid catabolism, lipistase was anticipated to decrease
body fat accumulation. In fact, lipistase treatment resulted in smaller
adipocytes and reduced body fat mass (Figures 1A and 3A and B). Fur-
thermore, macrophage infiltration of adipose tissue and associated
inflammatory markers, which are hallmarks of obesity,16 were much
reduced in the adipose tissue of lipistase-treated LDLrKO mice
(Figure 3A–C). Consistent with these observations, the mRNA levels
of diacylglycerol O-acyltransferase 2 (DGAT2) and of the major con-
stituent of the lipid droplet surface, the adipocyte differentiation-
related protein (ADFP), were decreased by lipistase treatment
(Figure 3D). In parallel, BFE and UCP3 were increased, most likely
reflecting an enhanced oxidative fatty acid catabolism (Figure 3E).
These results indicate that lipistase prevents adipose tissue expansion
and inflammation and increases its oxidative capacity.
To investigate a possible direct effect of lipistase on adipogenesis,
cultured 3T3L1 cells were induced to accumulate lipids with the
standard IBMX cocktail and then treated with either rosiglitazone, a
stimulator of adipogenesis, or rosiglitazone and lipistase. Lipistase pre-
vented triglyceride and neutral lipid (Oil-red O staining) accumulation
compared with cells treated with rosiglitazone alone (Figure 4A). Inter-
estingly, lipid loading was not significantly impacted by the PPARa
ligand WY-14 643, indicating that in this experimental cell culture
set-up, the lipistase effects do not depend on PPARa (Supplementary
material online, Figure S2). Lipistase did not inhibit genes involved in
adipocyte differentiation (PPARg2; CCAAT/enhancer binding
protein a, CEBPa; lipoprotein lipase, LPL), with the exception of adi-
pocyte protein 2 (aP2/FABP4), which was reduced (Figure 4B). Genes
encoding secreted adipokines, such as leptin, adiponectin, resistin, and
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Figure 1 Lipistase reduces body weight gain and body fat mass via PPARa activation. (A–C) Body weight gain, body fat mass, and plasma triglycer-
ides in lipistase-treated LDLrKO, LDLrKO-PPARaKO, and APOEKO mice vs. controls. (D) PPARa transactivation assay using the GAL4/UAS system.
NIH3T3 cells were transfected with either GAL4 (GAL4) alone or GAL4 linked to the PPARa LBD. The activators of PPARa bind to LBD and hence
trigger the transcription of a Luciferase reporter gene via binding of the GAL4 DNA-binding domain to the upstream activation sequence (UAS) in the
regulatory region of this gene. A Renilla reporter gene is used as a transfection control. LIP5SOY, LIP10SOY, LIP17SOY: lipistase at 5, 10, and 17 mg/L
of soy oil used at 1 mL/mL (final concentrations of lipistase: 5, 10, and 17 pg/mL of medium); Soy: soy oil as control of the effect of the lipistase vehicle
used at 1 mL/mL; WY-14 643 (wy): synthetic PPARa ligand used as positive control (1 mM as final concentration). Rapeseed oil, copra oil, evening
primrose oil, olive oil, and grape seed oil were all used at 1 mL/mL of medium [ns, not significant; *P, 0.05; ***P, 0.001; n(NIH3T3 cells, D) ¼ 2 × 3
wells].
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Figure 3 Lipistase reduces inflammation and impacts lipogenic and oxidative pathways in adipocytes of LDLrKO mice. (A) Anti-F4/80 immunostain-
ing of macrophages (appearing in brown) of epididymal white adipose tissue paraffin-embedded sections counterstained with haematoxylin and eosin
from animals after 10-month lipistase treatment vs. controls (bars ¼ 50 mm). (B) Adipocyte surface area (left) and F4/80 positive cells (right) were
quantified from representative sections. (C) mRNA expression levels of inflammatory markers and (D) of lipogenic markers. (E) Expression levels
of fatty acid transport and oxidation marker genes measured on white adipose tissue (*P, 0.05; **P, 0.01).
Figure 2 Lipistase enhances muscle lipid utilization in LDLrKO mice. (A) Representative images of anti-CD36 immunostaining on paraffin-embedded
sections of oxidative muscle (gastrocnemius) from mice after 10-month lipistase treatment vs. controls (bars ¼ 50 mm). (B) Oxygen consumption
measured after the 10-month treatment (***P, 0.001). (C) Immunoblot quantification of the membrane-bound CD36 protein in muscle and
mRNA expression of marker genes for fatty acid transport and oxidation measured in gastrocnemius 10 months after lipistase treatment (*P, 0.05).
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adipsin, were not affected either (Supplementary material online,
Figure S2B). However, the expression of four lipogenic genes
(steaoryl-CoA desaturase, SCD1; elongation of very long chain fatty
acids 3, Elovl3; diacylglycerol acyltransferase 1, DGTA1; DGAT2)
among the eight analysed was significantly reduced by lipistase
(Figure 4C, Supplementary material online, Figure S2C). Together,
these results indicate that lipistase downregulated the lipogenic
pathway both in vivo and in 3T3L1 cells, a likely cause for reduced
adipocyte lipid accumulation.
3.4 Liver steatosis
Lipistase prevented the development of a massive macrovacuolar liver
steatosis (Figure 5A). The lipistase-treated animals accumulated much
less cholesterol esters and triglycerides, which are hallmarks of the
steatotic condition, while the total cholesterol levels were not
changed (Figure 5B and Supplementary material online, Figure S3). It
is worth to note that the LDLrKO-PPARaKO mice accumulated
three to four times more neutral lipids on which lipistase had
less—but still significant for triglycerides—impact in the absence of
PPARa (Supplementary material online, Figure S3). The PPARa
effect in LDLrKO mice was associated with a lipistase-dependent
lower expression of lipogenic genes (Figure 5C) and significantly and
moderately higher expression of the fatty acid catabolism genes BFE
and UCP3, respectively (Figure 5D), which is reminiscent of the role
of lipistase in the adipose tissue.
Collectively, the decrease in adipose tissue mass and liver steatosis
and the increase in oxygen consumption provide evidence that
lipistase enhances fatty acid oxidation and attenuates lipogenesis
through regulation of the corresponding genes.
3.5 Lipistase-dependent PPARa activity
Previous work has attributed hypolipidaemic properties to PPARa.13
The similarity between the effects of lipistase and PPARa ligands, such
as fibrates, prompted us to assess whether the action of lipistase on
the expression of genes involved in fatty acid metabolism (CD36,
BFE, UCP3) and in lipogenesis (SCD1, Elovl3, DGAT2) is
Figure 4 Lipistase reduces lipogenesis in 3T3L1 differentiating cells. (A) Oil-red O staining (left panels; bars ¼ 50 mm) and quantification (right
panel) for 3T3L1 differentiated cells (day 8), treated with the PPARg ligand rosiglitazone (Rosi, 1 mM), the PPARa ligand WY-14643 (WY, 1 mM),
and lipistase (Lip, 160 pg/mL). *P ¼ 0.015. Lipistase effect on mRNA expression of (B) adipogenic transcription factors (PPARg2, CEBPa), adipose
differentiation markers (LPL, aP2), and (C) lipogenic enzymes (SCD1, Elovl3, DGAT1, and DGAT2) during differentiation of 3T3L1 cells at the indi-
cated days [**P, 0.01; n(3T3L1) ¼ 3 × 6 wells].
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PPARa-dependent. Gene expression analyses in lipistase-treated
LDLrKO and LDLrKO-PPARaKO mice provided evidence that
PPARa contributes to the regulation by lipistase of both analysed
pathways (Table 1 and Supplementary material online, Figure S4),
but the action of lipistase is not solely mediated by PPARa. Thus,
our results provide evidence for both independent and interactive
roles of lipistase and PPARa in lipid metabolism.
3.6 Prevention of atherosclerosis
To evaluate the effects of micronutrients on progression of athero-
sclerosis, we treated APOEKO mice with lipistase for up to 10
months after which an increase in oxygen consumption was observed
(Supplementary material online, Figure S5) similarly to LDLrKO mice
(Figure 2B). We also evaluated its effects on initiation of atherosclero-
sis in a third experiment: parent mice, gestating females, lactating
females, and post-weaning pups were all fed with lipistase for up to
3 months after weaning, at an age when atherosclerosis has normally
developed in untreated animals. Atherosclerotic plaque areas in aortic
roots of mice treated with lipistase in adulthood (starting at 10 weeks
of age) were not different from controls (Figure 6A). In contrast, mice
receiving early (at 3 weeks of age) or antenatal lipistase developed less
atherosclerosis at 3 months of age than their control mates (Figure 6B
and C; Supplementary material online, Figure S6A and B). Athero-
sclerotic plaques result from endothelial activation with the
expression of adhesion molecules and recruitment of macrophages
to the subendothelial space. Upon ingestion of modified lipoproteins,
Figure 5 Lipistase prevents hepatic steatosis. (A) Liver paraffin-embedded sections, stained with haematoxylin and eosin (upper panels) from
animals after 10-month lipistase treatment vs. controls (bars ¼ 100 mm); Oil-red O staining of equivalent sections (lower panels) (bars ¼ 50 mm).
(B) Levels of cholesterol esters and triglycerides in the liver of the same animals. (C) mRNA expression levels of lipogenic markers and (D) of
fatty acid transport and catabolism markers (*P, 0.05; **P, 0.01).
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these macrophages become foam cells17 and stimulate proliferation of
vascular smooth muscle cells, thereby leading to plaque growth.18
Antenatal lipistase treatment of APOEKO mice decreased VCAM1
and diminished CD68-positive plaque macrophages (Figure 6D).
Furthermore, lipistase reduced the number of aSMA-positive
smooth muscle cells in micronutrient-treated mice compared with
controls (Figure 6D). Since postprandial hypertriglyceridaemia is a
main risk factor of atherosclerosis,19 we tested the effect of the lipis-
tase treatment on this parameter. Lipistase reduced postprandial
hypertriglyceridaemia in mice with antenatal treatment (Supplemen-
tary material online, Figure S7). Importantly, lipistase did not have
adverse effects on fertility or pup survival (Supplementary material
online, Figure S8).
4. Discussion
The global escalation of obesity is a major health problem, but so far,
preventive measures have received little attention. Our study demon-
strates a preventive impact of a fine-tuned micronutrient combination
on obesity and atherosclerosis in different mouse strains. Indeed, in
LDLrKO and APOEKO mice, but less in LDLrKO-PPARaKO mice,
we observed a reduction in body weight gain, reflecting a lower fat
mass despite a similar food intake when compared with controls.
Lipistase treatment in LDLrKO mice increased lipid utilization by skel-
etal muscle and reduced fat accumulation in white adipose tissue and
liver by stimulating fatty acid uptake and catabolism and by reducing
lipogenesis. Lipistase administration in APOEKO mice had preventive
effects on atherogenesis, which was strongest in the offspring of
parents already treated with lipistase.
PPARa, which is known to reduce fat accumulation and athero-
sclerosis,13 was found to be activated by lipistase, revealing a role of
PPARa in participating in micronutrient actions. Previous work has
shown that reduction in body weight gain via PPARa activation is
mediated by an up-regulation of fatty acid oxidation and a decreased
de novo lipogenesis in liver and adipose tissue, respectively.13,20 Acti-
vated PPARa causes a reduction in plasma triglyceride levels by indu-
cing genes that decrease the availability of fatty acids for hepatic
triglyceride production, and genes that promote plasma triglyceride
clearance through lipoprotein lipase-dependent triglyceride lipolysis.21
Our data demonstrate that lipistase affects most of these pathways.
The primary site for triglyceride clearance and lipid utilization is the
skeletal muscle, an organ that plays a major role in the regulation of
triglyceridaemia and body weight.14 The fatty acid receptor CD36,
which is coded by a PPARa target gene in muscle, is one of the rate-
limiting factors for skeletal muscle lipid catabolism.22 Its expression
was increased by lipistase treatment in a PPARa-dependent manner,
suggesting an enhancement of lipid utilization and fatty acid oxi-
dation.23 Lipistase-treated mice showed increased whole-body
oxygen consumption, known to positively correlate with fat catabo-
lism in skeletal muscle.24,25 Stimulation of lipid utilization was reflected
in our study by decreased body fat mass, adipocyte size, and hepatic
steatosis. Supporting these observations, lipistase counteracted in vitro
the effects of rosiglitazone, a stimulator of adipogenesis. This effect
was not PPARa-dependent in cell culture showing that lipistase has
a broad spectrum of effects and is not merely a PPARa activator.
In our study, the anti-atherosclerotic effects observed upon lipis-
tase treatment are also reminiscent of those described for
PPARa.26–30 Lipistase effects were observed when APOEKO mice
were treated immediately after weaning and they were more pro-
nounced in animals for which treatment started already in their
parents. It remains to be determined whether lipistase unfolds its
effects mainly before or during gestation, lactation, or both and
whether epigenetic modifications are involved. Interestingly, recent
studies indicated that a parental diet may affect lipid metabolism in off-
spring. Epigenomic profiling of offspring livers revealed reproducible
changes in methylation over a likely enhancer for the PPARa
gene.31 Metabolic adaptations in utero to nutritional supply have
been shown to determine the risk of adult chronic diseases, such as
metabolic syndrome and atherosclerosis.32,33 The present study is
the first one to show that experimental atherosclerosis in mice can
be reduced by an antenatal nutritional intervention and hence offers
a prevention strategy to diminish foetal determinants of adult vascular
disease.
Further studies are required to address the safety profile of lipistase
treatment in terms of fertility, unharmed pregnancy, and breast-
feeding. The absence of difference in the litter size between treated
and control mice (under observation for 10 months: 14 litters per
group) and the normal morphology and behaviour of pups are
encouraging. If effective in humans, using lipistase in primary preven-
tion could contribute to fight the world pandemics of obesity and car-
diovascular diseases, in support of the World Health Organization
recommendation to begin prevention early in life.34
Endothelial dysfunction may be triggered by postprandial hypertri-
glyceridaemia35 and clearance of postprandial plasma triglycerides is
delayed in patients with atherosclerosis.36 In our antenatally treated
APOEKO mice, lipistase decreased postprandial plasma triglyceride
levels. In addition, lipistase-mediated increase in CD36 expression
in skeletal muscle suggests increased lipid uptake in muscle tissue.
These findings imply that lipistase reduces atherogenesis at least
in part by increasing postprandial plasma triglyceride clearance
through an elevated lipid uptake in skeletal muscle, the first tissue
destination of dietary lipids during the immediate postprandial
period.37 Obviously, several mechanisms by which lipistase may
prevent atherogenesis are possible and some of which may impli-
cate PPARa. Reduced intestinal absorption and/or an accelerated
plasma clearance of dietary fat are two of them to be studied in
the future.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 PPARa-dependent regulation by lipistase
Gene Muscle WAT Liver
FA uptake and catabolism
CD 36 + NE +
BFE + + +
UCP3 + + nd
Lipogenesis
SCD 1 NE + +
Elovl 3 2 NE +R
DGAT 2 2 2 +R
The effect of lipistase in LDLrKO mice and in LDLrKO-PPARaKO mice was compared
to determine the involvement of PPARa in the lipistase-dependent action. The data
are derived from results show in Figures 2–4 and in Supplementary material online,
Figure S3. NE, no effect of lipistase; +, PPARa-dependent effect of lipistase; 2 , no
PPARa-dependent effect of lipistase; +R, PPARa-dependent effect of lipistase;
inversed effect in LDLrKO-PPARaKO; nd, not determined.
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Taken together, our results demonstrate beneficial effects of this
novel combinatorial micronutrition on obesity, hypertriglyceridaemia,
liver steatosis, and atherosclerosis that are mediated in part by PPARa
and achieved through enhanced lipid utilization by skeletal muscle, as
well as increased oxidative capacity and reduced lipid accumulation in
adipose tissue and liver. In contrast to cholesterol lowering agents,
which should be avoided in pregnancy and/or lactation,38 the combi-
nation of micronutrients analysed in mice seems to be safe. Lipistase
represents a nutraceutical that could be taken as tablet or included into
human food such as diary products. Thus, double-blind placebo-
controlled lipistase studies in small patient cohorts are the next
logical step to assess its value with regard to body fat accumulation,
plasma lipids, and vascular disease. Moreover, the complex combina-
torial mode and the low doses of micronutrients used introduce a
novel concept and highlight the attractive potential of micronutrition-
based, cost-effective preventive interventions.
Figure 6 Lipistase confers atheroprotection in APOEKO mice. (A) Graph represents area of atherosclerotic lesions in aortic roots from mice
treated with lipistase (10 mice) or vehicle (Control, 8 mice) starting at 10 weeks of age for 10 months. (B) The graph illustrates atherosclerotic
plaque area in aortic roots (lipistase, eight animals; control, eight animals) from mice treated with lipistase or vehicle (Control) starting at 3 weeks
of age for 3 months. (C) The graph shows plaque area in aortic roots (15 animals) from offspring of lipistase- or vehicle- (control) treated mice.
These offsprings were also treated after weaning for 3 months. (D) Anti-VCAM1, anti-CD68, and anti-aSMA immunostaining (red) of aortic roots
from the offspring of lipistase- or vehicle-treated mice (DAPI, blue) (left panels) with corresponding quantification (graphs, right panels). Samples
from the same animals as in (C) are shown (bars ¼ 200mm) (ns, not significant; *P, 0.05; **P, 0.01; ***P, 0.001).
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Supplementary material is available at Cardiovascular Research online.
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